A clinical study of mesenchymal stromal cell therapy for patients with acute graft-versus-host disease (aGVHD) and acute respiratory distress syndrome (ARDS)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 Oct 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Mesenchymal stromal cell therapy-Avalon GloboCare (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections; Graft-versus-host disease
Focus Adverse reactions; First in man

01 Oct 2020 According to a Avalon GloboCare media release, this study is expected to begin in Q4 2020.
10 Sep 2020 New trial record
03 Sep 2020 According to a Avalon GloboCare media release, the company expect to initiate this study during the first half of 2021, assuming clearance from U.S. and/or non-U.S. regulatory agencies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com